Jazz Pharms Res Drug Patent Portfolio

Jazz Pharms Res owns 1 orange book drug protected by 31 US patents Given below is the list of Jazz Pharms Res's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11160795 Methods of treating tuberous sclerosis complex with cannabidiol and everolimus 01 Mar, 2041
Active
US11406623 Methods of treating tuberous sclerosis complex with cannabidiol and everolimus 01 Mar, 2041
Active
US11207292 Cannabidiol preparations and its uses 26 Apr, 2039
Active
US11865102 Cannabidiol preparations and its uses 26 Apr, 2039
Active
US10918608 Use of cannabidiol in the treatment of epilepsy 13 Oct, 2035
Active
US11065209 Use of cannabidiol in the treatment of epilepsy 13 Oct, 2035
Active
US11096905 Use of cannabinoids in the treatment of epilepsy 13 Oct, 2035
Active
US11400055 Use of cannabidiol in the treatment of epilepsy 13 Oct, 2035
Active
US10092525 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US10111840 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US10137095 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US10603288 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US10709671 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US10709673 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US10709674 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US10849860 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US10966939 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US11154516 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US11311498 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US11357741 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US11446258 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US11633369 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US11701330 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US11766411 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US11963937 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US9949937 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US9956183 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US9956184 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US9956185 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US9956186 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
Active
US10195159 Processes and apparatus for extraction of active substances and enriched extracts from natural products 07 May, 2022 Expired


Given below is the list of recent legal activities going on the following drug patents of Jazz Pharms Res.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 17 Jul, 2024 US10918608
Email Notification 21 Jun, 2024 US10709673
Change in Power of Attorney (May Include Associate POA) 21 Jun, 2024 US11096905
Email Notification 21 Jun, 2024 US11406623
Email Notification 21 Jun, 2024 US9956184
Change in Power of Attorney (May Include Associate POA) 21 Jun, 2024 US10092525
Change in Power of Attorney (May Include Associate POA) 21 Jun, 2024 US9956184
Email Notification 21 Jun, 2024 US10092525
Email Notification 21 Jun, 2024 US11096905
Change in Power of Attorney (May Include Associate POA) 21 Jun, 2024 US11406623
Change in Power of Attorney (May Include Associate POA) 21 Jun, 2024 US10709673
Email Notification 18 Jun, 2024 US9956185
Change in Power of Attorney (May Include Associate POA) 18 Jun, 2024 US9956185
Change in Power of Attorney (May Include Associate POA) 17 Jun, 2024 US10137095
Email Notification 17 Jun, 2024 US10709671


Jazz Pharms Res Drug Patents' Oppositions Filed in EPO

Jazz Pharms Res drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 29, 2021, by James Poole Limited. This opposition was filed on patent number EP15784111A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15784111A Apr, 2021 James Poole Limited Granted and Under Opposition


Jazz Pharms Res's Family Patents

Jazz Pharms Res drugs have patent protection in a total of 25 countries. It's US patent count contributes only to 25.1% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Jazz Pharms Res Drug List

Given below is the complete list of Jazz Pharms Res's drugs and the patents protecting them.


1. Epidiolex

Epidiolex is protected by 31 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11160795 Methods of treating tuberous sclerosis complex with cannabidiol and everolimus 01 Mar, 2041
(16 years from now)
Active
US11406623 Methods of treating tuberous sclerosis complex with cannabidiol and everolimus 01 Mar, 2041
(16 years from now)
Active
US11207292 Cannabidiol preparations and its uses 26 Apr, 2039
(14 years from now)
Active
US11865102 Cannabidiol preparations and its uses 26 Apr, 2039
(14 years from now)
Active
US10918608 Use of cannabidiol in the treatment of epilepsy 13 Oct, 2035
(11 years from now)
Active
US11065209 Use of cannabidiol in the treatment of epilepsy 13 Oct, 2035
(11 years from now)
Active
US11096905 Use of cannabinoids in the treatment of epilepsy 13 Oct, 2035
(11 years from now)
Active
US11400055 Use of cannabidiol in the treatment of epilepsy 13 Oct, 2035
(11 years from now)
Active
US10092525 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US10111840 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US10137095 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US10603288 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US10709671 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US10709673 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US10709674 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US10849860 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US10966939 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US11154516 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US11311498 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US11357741 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US11446258 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US11633369 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US11701330 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US11766411 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US11963937 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US9949937 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US9956183 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US9956184 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US9956185 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US9956186 Use of cannabinoids in the treatment of epilepsy 17 Jun, 2035
(10 years from now)
Active
US10195159 Processes and apparatus for extraction of active substances and enriched extracts from natural products 07 May, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epidiolex's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List